Xenon制药 XENE 深 沪
已收盘 02-06 16:00:00 美东时间
41.42
+1.030
+2.55%
华盛通- 最 高46.3566
- 今 开41.09
- 成交量 50.61万股
- 最 低 39.29
- 昨 收 40.39
- 总市值 219.96万
- 52周最高 46.60
- 市盈率 静 --
- 换手率 952.97%
- 52周最低 26.74
- 委 比 -62.75%
- 总股本 5.31万
- 历史最高 50.99
- 量 比 0.84
- 振 幅 17.50%
- 历史最低 1.10
- 每 手 1
- 风险率 4.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biohaven Misses The Mark In Depression Trial, Stock Falls
Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depressive symptoms in comparison to placebo.
2025-12-26 21:20
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
2025-11-03 19:11
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Xenon Pharmaceuticals Inc. will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. The Fireside Chat will take place from 3:20-3:55 PM ET, led by President and CEO Ian Mortimer. A live webcast is available on Xenon's investor website, with registration details provided.
2025-06-03 20:01
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vancouver and Boston, May 30, 2025 (GLOBE NEWSWIRE) – Xenon Pharmaceuticals Inc. granted 53,550 share options to seven new employees under Nasdaq Rule 5635(c)(4), with an exercise price of $29.04 per share. The options vest over four years with 25% vesting after the first year and monthly vesting thereafter.
2025-05-30 20:01
2025年美股Biotech有望大涨 摩根大通首选福泰制药
华尔街金融巨头摩根大通近日发布研报称，对于2025年美股市场的生物科技公司（即Biotech）股价走势持乐观看涨立场，预计Biotech有望跑赢美股大盘，其中美股Biotech领军者之一的福泰制药（VRTX.US）在摩根大通的2025年最佳Biotech选股名单中位列榜首。在美联储开启降息的大背景下，生物科技类股票可谓是最佳受益于降息周期的股票板块，在降息周期之下资金有望从近年来股价持续暴涨且估值处于历史高位的大型科技巨头们转向一些受益于降息周期且估值自2022年以来长期低迷的生物科技股。 据了解，在摩根大通最新发布的研报中，该机构2025年最看好的生物科技公司除了位列股票名单首选位置...
2024-11-26 15:22
